Proactive Investors - Run By Investors For Investors

LeanLife shares pop in anticipation of distribution of Omega-3 samples in Europe

Shares rose more than 11% after news that LeanLife’s proprietary Omega-3 product will be distributed to a consumer base of some of the continent’s largest food producers
leanlife omega 3
Samples of LeanLife's Omega-3 products have arrived in Europe for distribution

LeanLife Health Inc (CSE:LLP) announced Tuesday that its first Omega-3 product samples are ready for distribution in Europe.

Shares of LeanLife popped on the news, up 11.1% at C$0.05 by midday Tuesday.

The Vancouver-based company develops proprietary plant-based food products that can be used as food additives or nutraceuticals. It has a patented process to isolate Omega-3 fatty acids from flax seeds.

READ: LeanLife hits new milestone, ships first Omega-3 product samples

LeanLife’s proprietary Omega-3 product will be distributed to a consumer base of some of the continent’s largest producers of bread, pasta, cheese, yogurt and butter.

"With the samples now available for distribution in Europe and confirmation of the quality and specifications of our propriety Omega-3 product underway, our experienced sales and industry expert will soon be visiting some of Europe's largest food producers," said Stan Lis, LeanLife’s CEO.

Recently, a trial application using the Omega-3 product as a substitute for vegetable oil showed negligible difference in taste and quality, LeanLife said in a statement.

The testing resulted in the production of samples which will now be evaluated by SGS, a third-party accredited lab.

According to the extract manufacturer, the company is ready to begin large-scale production and fulfill multiple orders following the validation of samples by buyers.

The global Omega-3 market reached US$33 billion in 2016 and is expected to reach upwards of US$57 billion by 2025, according to a report by Grand View Research Inc.

The company also announced that it has granted stock options to officers, directors and consultants of LeanLife entitling them to purchase a combined total of 3.9 million shares at C$0.05 per share.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

View full LLP profile View Profile

LeanLife Health Timeline

February 07 2019

Related Articles

A woman with severe depression
April 25 2019
The New York clinical-stage biopharmaceutical company has several drugs in the pipeline capable of generating hefty revenue
Medical scanner
February 08 2019
The company’s digital platform and Artificial Intelligence (AI) software manages and helps interpret images from MRI (magnetic resonance imaging) and PRT (positron emission tomography) scanners
man with erectile dysfunction
Headline results from the trial of MED2005 are due before the end of 2019, while Futura is also confident of hearing back from UK regulators about its pain relief gel later in the year
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use